Ozenoxacin is a synthetic non-fluorinated quinolone antibiotic compound used as an active pharmaceutical ingredient (API) in topical formulations for the treatment of impetigo, a common bacterial skin infection. It inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and effectively eliminating susceptible bacteria such as Staphylococcus aureus and Streptococcus pyogenes. The pure compound is an off-white solid with high purity (≥99%), suitable for pharmaceutical manufacturing. When formulated as a 1% cream, it is applied topically to the affected area twice daily for 5 days, providing localized treatment with minimal systemic absorption. This makes it safe for adults and children over 2 months, reducing the risk of antibiotic resistance.